CD274 and head and neck squamous cell carcinoma: Although immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockers) have emerged as a cornerstone of HNSCC therapy, their clinical efficacy remains limited to a subset of patients, reflecting the complexity and heterogeneity of the TME in modulating treatment responses (11).